Chronic Granulomatous Disease (CGD)
CGD is a primary immunodeficiency caused by defects in the NADPH oxidase complex, leading to impaired neutrophil killing of catalase-positive bacteria and fungi. Patients suffer recurrent infections and granulomatous inflammation affecting lungs, liver, skin, GI tract, and lymph nodes.
Genetics
- X-linked CGD (gp91phox/CYBB gene) ~70% of cases
- Autosomal recessive mutations (p47phox, p67phox, p22phox, p40phox)
- Carrier females may have mild symptoms due to lyonization
Symptoms & Infections
- Recurrent pneumonia, skin abscesses, lymphadenitis
- Hepatic abscesses, osteomyelitis
- Nocardia, Serratia, Burkholderia, Aspergillus infections
- Granulomatous colitis mimicking Crohn’s disease
- Failure to thrive in severe cases
Diagnosis
- Dihydrorhodamine (DHR) flow cytometry assay (preferred) or nitroblue tetrazolium test
- Genetic testing for mutation confirmation and counseling
- Work-up for infections (culture, imaging) when symptomatic
Management
Infection Prophylaxis
- Daily trimethoprim-sulfamethoxazole and itraconazole (or posaconazole)
- Interferon-gamma injections three times weekly to boost oxidative burst
- Prompt evaluation of fevers; low threshold for IV antibiotics
- Avoid mulch/pottery/soil exposure (Aspergillus risk)
Treating Infections
- Aggressive surgical drainage of abscesses
- Prolonged courses of antibiotics/antifungals guided by culture
- Corticosteroids for severe inflammatory complications (e.g., obstructive granulomas) alongside antimicrobials
Curative Options
- Allogeneic hematopoietic stem cell transplant (HSCT) recommended for severe phenotypes; survival exceeds 90% in experienced centers
- Gene therapy (lentiviral vectors) showing durable neutrophil correction in trials
Supportive Care
- Monitor liver function, inflammatory bowel disease, growth, and nutrition
- Vaccinations (avoid live vaccines unless specialist approves)
- Psychological support—frequent hospitalizations are stressful
Living with CGD
- Track prophylaxis doses, interferon injections, infections, cultures, imaging, HSCT evaluations
- Educate schools/employers about infection risk
- Plan travel carefully (carry antibiotics, avoid high-risk environments)
- Maintain communication with immunology team for early intervention
Complications
- Chronic lung disease, pulmonary fibrosis
- GI granulomas causing obstruction
- Autoimmune/inflammatory complications (lupus-like syndromes)
- Side effects of long-term antifungals or interferon
Research & Future Directions
Gene therapy improvements, CRISPR editing, and targeted anti-inflammatory agents aim to reduce morbidity without lifelong prophylaxis.
Experimental & Emerging Treatments
- Lentiviral Gene Therapy: Autologous stem cells corrected ex vivo show sustained NADPH oxidase activity.
- CRISPR Editing: Precise corrections for X-linked CGD in preclinical stages.
- Targeted Biologics: TNF inhibitors or IL-1 blockers in refractory granulomatous inflammation (cautiously, with infection prophylaxis).
- Microbiome & Anti-Biofilm Strategies: Prevent colonization by high-risk pathogens.
Track CGD with Diagnoza.care
Stay Ahead of Infections – Log prophylaxis adherence, interferon injections, lab results, imaging, infections, hospitalizations, HSCT/gene therapy milestones, and mental health check-ins; capture side effects; and let the AI companion remind you of labs, vaccines, and early warning signs.
Medical Disclaimer: Informational only. Work with your immunologist/infectious disease team for prophylaxis regimens, emergency action plans, and transplantation/gene therapy decisions.
Sources: Immune Deficiency Foundation, Primary Immune Deficiency Treatment Consortium, National Institutes of Health